1 completed, 1 unknown. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Corestemchemon, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients CS20AT04 (allogenic bone marrow derived mesenchymal stem cell) - Systemic Lupus Erythematosus | Phase 2 | Unknown | Hanyang University Seoul Hospital | 10 | 2019-09-26 | 2021-04-08 |
| Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis HYNR-CS inj, Control group - Amyotrophic Lateral Sclerosis, ALS | Phase 1 / Phase 2 | Completed | Corestemchemon, Inc. | 72 | 2011-02-01 | 2022-03-17 |
Amyotrophic Lateral Sclerosis (1) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Motor Neuron Disease (1)
Control Groups (1)
South Korea (2)
Chan-Bum Choi, M.D.,Ph.D. (1) · Seung Hyun Kim, M.D., Ph.D. (1)